NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

• Status: Completed
• Trial end date: 2006-09-05
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 1 diabetes mellitus

• Type 2 diabetes mellitus

• Other types of diabetes mellitus (gestational, drug induced [thiazide] or metabolic syndrome-related)